vimarsana.com

Page 89 - நரம்பியல் அறுவை சிகிச்சை சிகிச்சையகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Promising nanobodies against COVID-19 produced by llamas

Promising nanobodies against COVID-19 produced by llamas Thought LeadersDr. David BrodyProfessor of NeurologyUniformed Services University In this interview, News-Medical speaks to Dr. David Brody about his latest research that involved discovering nanobodies produced by llamas that could help combat coronavirus. What provoked your research into the ongoing COVID-19 pandemic? We are neuroscientists, so it was a bit of a shift in direction! For several years TJ and I had been testing out how to use nanobodies to make brain imaging better. When the pandemic broke, we thought this is a once in a lifetime, all-hands-deck situation and joined the fight.

NTU Singapore launches new strategic plan, remaking learning, innovation and interdisciplinary collaboration

Date Time NTU Singapore launches new strategic plan, remaking learning, innovation and interdisciplinary collaboration Nanyang Technological University, Singapore (NTU Singapore) today unveiled its NTU 2025 strategic plan which details the University’s education, research and innovation ambitions and goals for the next five years and offers a roadmap to achieve them.  At the top of its ambitious agenda for NTU 2025, the university will introduce new paradigms that respond to the changes brought about by the accelerating pace of technology, and to the challenges facing humanity in the post-COVID world. To transform learning at NTU, undergraduates will be offered new interdisciplinary degree programmes, core curricula and internships to enrich their disciplinary training. NTU will also establish a new Institute for Pedagogical Innovation, Research and Excellence (InsPIRE). 

Harvard spin-off CELLVIE closes $5M seed round for therapeutic mitochondria transfer

$5M financing round led by Kizoo Technology Capital Fresh capital to be employed for productization, to prepare a clinical trial in organ transplantation and to expand cellvie s pipeline into rejuvenation therapies Promising initial clinical data generated at Boston Children s Hospital to be published in the Journal of Thoracic and Cardiovascular Surgery Zurich/Switzerland and Houston/USA, January 25, 2021: cellvie Inc., the leader in Therapeutic Mitochondria Transfer (TMT) and a Harvard University spin-off, closes a $5M round to advance its product pipeline, including a first application in rejuvenation. Mitochondria are intimately tied to the origin of complex life, the energy of the young and the decline of the old. They are the powerhouses of the cell, generating most of the cellular energy and operate as critical intra-cellular communication nodes. Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments such as Parkinson s and

Fine tuning first-responder immune cells may reduce TBI damage

Immediately after a traumatic brain injury and as long as one year later, there are increased levels of immune cells called ILCs in the brain promoting inflammation, which can worsen brain damage, scientists report. They also report for the first time that the cell energy sensor AMPK is a brake that can stop what becomes a chronic state of destructive inflammation driven by these ILCs, or innate lymphoid cells.

Better technique to speed up pain research

Photo: Pixabay Scientists have for the first time established a sensory neuron model able to mass-reproduce two key sensory neuron types involved in pain sensation, enabling the easy generation of large numbers of the cells to fast-track chronic pain research. In research applications usually sensory neurons need to be isolated from animals. They represent a wide variety of different cell types, making it difficult to collect and isolate large quantities of pain sensing neurons. Using a new technique, researchers at Flinders University have found a way to reproduce millions of the cells, providing ample resources for the simultaneous testing of thousands of samples or potential drug libraries.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.